McKesson will exclusively distribute Sysmex's XW-100 system, a CLIA-waived complete blood count diagnostic instrument starting in the spring.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
Microgenics, Astute Medical, and Siemens were among the firms whose tests and/or systems were cleared by the FDA for marketing last month.
Sysmex said that in 2018, it will replace LifeLabs' hematology analyzers at 12 sites throughout British Columbia and Ontario and provide scalable solutions.
The alliance follows a marketing deal signed with Sysmex Europe that covers Europe, the Middle East, and Africa.
The XW-100 Automated Hematology Analyzer previously received 510(k) clearance. With the CLIA waiver, the test can be run in more types of healthcare facilities.
The firm said that entry into the market is a logical progression based on its existing position and strength in hematology, an adjacent segment.
The collaboration among the National Cancer Center Japan, JVCKENWOOD, Sysmex, and Daiichi Sankyo aims to detect cancer-specific exosomes from patients' blood.
The two companies plan to secure required initial regulatory approvals in individual African territories before expanding to other areas in the region.
The subsidiary of Sysmex is evaluating two liquid biopsy technologies for their abilities to monitor patient response to chemotherapy in breast cancer patients.